BRISBANE, Calif., April 20 /PRNewswire-FirstCall/ -- WHAT: VaxGen, Inc. Senior Vice President, Research & Development, Kathrin Jansen, Ph.D., will give a presentation titled “Development of a Recombinant Anthrax (rPA) Vaccine” at the pre-conference symposium of the 4th Annual Bio-Chem Defense & Pandemic Vaccines & Therapeutics Conference in Washington, D.C. WHEN/ WHERE: 8:30 a.m. ET, Monday, April 24, 2006 Almas Temple Club, Washington, D.C. About VaxGen
VaxGen, Inc. is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious diseases, including anthrax and smallpox. VaxGen has been awarded an $877.5 million contract by the U.S. Department of Health and Human Services to provide 75 million doses of a recombinant anthrax vaccine for civilian biodefense. Based in Brisbane, Calif., VaxGen operates a wholly owned manufacturing facility in California and owns 21% of Celltrion, Inc., a company in the Republic of Korea established to provide contract manufacturing to the global pharmaceutical industry. For more information, please visit the company’s web site at www.vaxgen.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comVaxGen, Inc.
CONTACT: Paul Laland of VaxGen, Inc., +1-650-624-2345
Web site: http://www.vaxgen.com//
